Table 3.
Summary of BICR-Assessed Best Overall Confirmed Responses in Patients With Tumors Harboring Target Gene Fusions, According to Fusion Kinase and Tumor Type
| Response, n (%) | Fusion Kinase | Tumor Type | Total (n = 26) | |||
|---|---|---|---|---|---|---|
| NTRK1/2/3 (n = 15) | ROS1 (n = 8) | ALK (n = 3) | Primary CNS (n = 16) | Extracranial Solid (n = 10) | ||
| Objective response rate, % (95% CI) | 60.0 (32.3, 83.7) | 62.5 (24.5, 91.5) | 33.3 (0.84, 90.6) | 50.0 (24.7, 75.4) | 70.0 (34.8, 93.3) | 57.7 (36.9, 76.7) |
| Complete response | 5 (33.3) | 1 (12.5) | 1 (33.3) | 4 (25.0) | 3 (30.0) | 7 (26.9) |
| Partial response | 4 (26.7) | 4 (50.0) | 0 | 4 (25.0) | 4 (40.0) | 8 (30.8) |
| Stable disease | 4 (26.7) | 2 (25.0) | 1 (33.3) | 5 (31.3) | 2 (20.0) | 7 (26.9) |
| Progressive disease | 1 (6.7) | 0 | 1 (33.3) | 2 (12.5) | 0 | 2 (7.7) |
| Missing/unevaluable | 1 (6.7) | 1 (12.5) | 0 | 1 (6.3) | 1 (10.0) | 2 (7.7) |
Abbreviations: ALK, anaplastic lymphoma kinase; BICR, blinded independent central review; CI, confidence interval; CNS, central nervous system; CR, complete response; NTRK, neurotrophic tyrosine receptor kinase; PD, progressive disease; ROS1, ROS proto-oncogene 1.